People who microdose psychedelics like psilocybin or LSD are most often doing so to improve their mental health, for personal development, or to enhance cognitive performance. A 2018 international online survey of 525 current microdosers found that the perceived short-term benefits cluster into three areas: improved mood and reduced anxiety, a greater sense of connection to others and the environment, and cognitive enhancement. Unwanted effects included stronger-than-expected psychedelic effects, anxiety-related effects, and physical adverse effects. Most participants (78%) reported using at least one harm reduction practice. The findings indicate that microdosing is commonly used as a self-managed mental health therapy, often as an alternative or complement to conventional treatments.
An international online survey of 1102 people who had microdosed psychedelics found that 21% did so primarily for depression, 7% for anxiety, 9% for other mental disorders, and 2% to reduce or stop substance use. Forty-four percent perceived their mental health as "much better" as a result. Perceived improvements were associated with gender, education, microdosing duration and motivations, and recent use of larger psychedelic doses. The authors call for clinical trials to determine microdosing's potential role in psychiatric treatment and for further social research on its use as a self-managed therapy.